Navigation Links
ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
Date:10/24/2007

Enrollment completed in separate Phase II study in Carotid Atherosclerosis

LEXINGTON, Mass., Oct. 24 /PRNewswire/ -- ActivBiotics, Inc. today announced that the results of its pivotal clinical trial (PROVIDENCE-1) studying the effect of rifalazil in the treatment of intermittent claudication associated with peripheral arterial disease (PAD) will be presented on November 7, 2007 at 11:45 a.m. EST at a late breaker Scientific Session at the American Heart Association's 2007 annual meeting being held in Orlando, Florida. Michael R. Jaff, DO, FACP, FACC, Assistant Professor of Medicine, Harvard Medical School and Medical Director, Massachusetts General Hospital Vascular Center, Boston, Massachusetts, Chair of the trial's Steering Committee, will be presenting.

PROVIDENCE-1 (Prospective Evaluation of Rifalazil Effect on Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients) is the first of two planned Phase III clinical trials to study the ability of rifalazil to improve symptoms in patients suffering from intermittent claudication, an often debilitating and under diagnosed manifestation of PAD. The prospective, double-blind, randomized, placebo- controlled trial evaluated the efficacy and safety of rifalazil in 297 patients from the United States, Russia and Brazil. The FDA has granted rifalazil Fast Track designation for development in this indication.

In addition to the PROVIDENCE-1 Phase III clinical trial, a Phase II study to evaluate the effect of rifalazil on the progression of carotid artery atherosclerosis has completed its target enrollment of 72 patients. The RESTORE-IT trial (Randomized Evaluation of Short-Term Rifalazil Treatment on Carotid Atherosclerosis and Intima Media Thickness) is a prospective, randomized, double-blind, placebo-controlled, multi-center study of patients with a clinical history of atherosclerosis and image-detectable carotid disease. This study will use the non-invasive imaging techniques of combined high-resolution magnetic resonance imaging and ultrasound to assess the degree of architectural changes in the carotid artery brought about by rifalazil treatment. The presence and progression of carotid disease are strongly correlated with an increased incidence of cardiovascular and stroke events.

Chlamydia pneumoniae infection of the vascular system has long been thought to play a role in accelerating the course of vascular disease potentially by increasing inflammation in the arterial wall thus leading to exacerbation of atherosclerosis, which could reduce blood supply to target limbs and organs.

About ActivBiotics, Inc.

ActivBiotics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of inflammatory diseases and bacterial infections. For more information on ActivBiotics, Inc., please visit our web site at: http://www.activbiotics.com.

Safe Harbor Statement

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates" or the negation thereof, or similar expressions, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of ActivBiotics, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. For those statements, ActivBiotics, Inc. claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. ActivBiotics, Inc. will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... Like Us ( https://explorerslikeus.com/ ) is embarking on "An American ... these experiences as part of Life Environments™, a new technology ... ... beats a walk, jog or simply playing in a garden ... next best thing when getting there isn’t possible. Life Environments™ ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who play ... Spirit: “Love”” is the creation of published author, Halimah Jones, who was born and ... an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from her ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance (GLA), ... education and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. as ... has more than 20 years of research experience with Lyme and other tick-borne ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... SABRE is ... run from September 11 to the end of November. , The Chicago, Illinois, based ... their community and teach them about the ease of taking their personal safety into ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... in their communities, nine governmental public health departments have been awarded five-year accreditation ... decisions mean that the benefits of being served by a PHAB-accredited health ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for ... today the election of Yie-Hsin Hung to the Board of Directors. , “The ... of Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, ...
Breaking Medicine News(10 mins):